Novo Nordisk partners with US biotech company on diabetes

Novo Nordisk will fund further preclinical development of potential drug candidates.

by MARKETWIRE

Novo Nordisk has entered into a collaboration with US-based Biosplice Therapeutics to develop small molecule drugs for the treatment of diabetes, an announcement from the American company states.

Under the agreement, Novo Nordisk will fund further preclinical development of potential drug candidates and Novo Nordisk will also have an exclusive option to in-license Biosplice’s rights in cardiometabolic diseases such as obesity, diabetes and cardiovascular disease.

Financial details of the agreement have not been disclosed, but it involves an upfront payment, milestone payments and royalties, according to Biosplice, based in San Diego, California.

English edit: Catherine Brett

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

UK court gives NHS green light to claim damages against Lundbeck

Although it is more than ten years since the European Commission ruled that Lundbeck entered into illegal pay-for-delay agreements regarding the drug Citalopram, the NHS can still claim compensation.

Lundbeck to test drug candidate as treatment for Cushing's syndrome

Lundbeck CEO assembles dream executive team to "transform" business

For subscribers

Albert Bourla, CEO of Pfizer, announced on Monday that the company is testing three potential weight loss drugs.

Pharma & biotech

Pfizer is testing three new weight loss candidates

For subscribers

Pharma & biotech

Teva to launch generic copy of Novo Nordisk drug in the US

Pharma & biotech

FDA accepts Lundbeck's application for Rexulti as supplementary PTSD treatment

Pharma & biotech

Eli Lilly appoints Nordic Head of Public Affairs

For subscribers

Pharma & biotech

Wegovy approved in China

Novo Nordisk announces USD 4.1bn factory expansion in North Carolina
After months of speculation, Novo Nordisk has formally announced its plans to expand production facilities in Clayton.
Zealand Pharma is very open to partnership after promising obesity data
The company’s weight-loss drug Petrelintid has just delivered positive results.
Underdog obesity drug performs well in Phase II study
Altimmune has shown that the company’s weight loss drug pemvidutid predominantly provides weight loss from lost fat mass, rather than muscle.
For subscribers
ALK withdraws Chinese application for allergy tablet and raises guidance
The company now expects revenue growth of 12-15%.
For subscribers
Novo Nordisk tightens security after fire: "Until now it was built on trust"
After a fire and the discovery of undocumented workers at the site, security guards are being hired at Novo Nordisk’s future factory in Kalundborg.
For subscribers
Novo Nordisk's hemophilia candidate shows signs of greater efficacy than other agents
New phase III data also shows that Novo’s potential hemophilia drug is less effective for patients who have previously used other medicines.
For subscribers

Pfizer is testing three new weight loss candidates

Two of the experimental drugs are GLP-1 agents.

For subscribers

Pharma & biotech

Teva to launch generic copy of Novo Nordisk drug in the US

Sales of type 2 diabetes drug Victoza dropped last year.

Pharma & biotech

UK court gives NHS green light to claim damages against Lundbeck

Although it is more than ten years since the European Commission ruled that Lundbeck entered into illegal pay-for-delay agreements regarding the drug Citalopram, the NHS can still claim compensation.

For subscribers